Amitabh Gulati

Amitabh Gulati

Auto-generated profile, based on publicly available information

Amitabh Gulati

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Pain Medicine
Verified
Journal Article
Open access
PDF file
TLTiffany Lin
Tiffany Lin
AGAkshat Gargya
Akshat Gargya
HSHarmandeep Singh
Harmandeep Singh
ESEellan Sivanesan
Eellan Sivanesan
AGAmitabh Gulati
Amitabh Gulati
Introduction: With the advancement of technology, peripheral nerve stimulation (PNS) has been increasingly used to treat various chronic pain conditions. Its origin is based on the gate control theory postulated by Wall and Melzack in 1965. However, the exact mechanism behind PNS’ analgesic effect is largely unknown. In this article, we performed a comprehensive literature review to overview the PNS mechanism of action.Design: A comprehensive literature review on the mechanism of PNS in chronic pain.Methods: Comprehensive review of the available literature on the mechanism of PNS in chronic pain. Data were derived from database searches of PubMed, Scopus, and the Cochrane Library and manual searches of bibliographies and known primary or review articles.Results: Animal, human, and imaging studies have demonstrated the peripheral and central analgesic mechanisms of PNS by modulating the inflammatory pathways, the autonomic nervous system, the endogenous pain inhibition pathways, and involvement of the cortical and subcortical areas.Conclusions: Peripheral nerve stimulation exhibits its neuromodulatory effect both peripherally and centrally. Further understanding of the mechanism of PNS can help guide stimulation approaches and parameters to optimize the use of PNS.

1 July 2021 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
MAMansoor M Aman
Mansoor M Aman
AMAmmar Mahmoud
Ammar Mahmoud
TDTimothy R. Deer
Timothy R. Deer
DSDawood Sayed
Dawood Sayed
JHJonathan M Hagedorn
Jonathan M Hagedorn
SNSanjeet Narang
Sanjeet Narang
Moderate to severe pain occurs in many cancer patients during their clinical course and may stem from the primary pathology, metastasis, or as treatment side effects. Uncontrolled pain using conservative medical therapy can often lead to patient distress, loss of productivity, shorter life expectancy, longer hospital stays, and increase in healthcare utilization. Various publications shed light on strategies for conservative medical management for cancer pain and a few international publications have reviewed limited interventional data. Our multi-institutional working group was assembled to review and highlight the body of evidence that exists for opioid utilization for cancer pain, adjunct medication such as ketamine and methadone and interventional therapies. We discuss neurolysis via injections, neuromodulation including targeted drug delivery and spinal cord stimulation, vertebral tumor ablation and augmentation, radiotherapy and surgical techniques. In the United States, there is a significant variance in the interventional treatment of cancer pain based on fellowship training. As a first of its kind, this best practices and interventional guideline will offer evidenced-based recommendations for reducing pain and suffering associated with malignancy.

2 September 2016 in Pain Practice
Verified
Journal Article
Closed access
PDF file
JZJennifer A. Zocca
Jennifer A. Zocca
GCGrant H. Chen
Grant H. Chen
VPVinay G. Puttanniah
Vinay G. Puttanniah
JHJoseph C. Hung
Joseph C. Hung
AGAmitabh Gulati
Amitabh Gulati

17 March 2020 in Neuromodulation: Technology at the Neural Interface
Verified
Journal Article
Open access
PDF file
OMOjas Mainkar
Ojas Mainkar
CSChe Antonio Solla
Che Antonio Solla
GCGrant H. Chen
Grant H. Chen
ALAron Legler
Aron Legler
AGAmitabh Gulati
Amitabh Gulati
Objectives Temporary, percutaneous peripheral nerve stimulation (PNS) has been shown to provide analgesia for acute postoperative pain, postamputation pain, and low back pain. The implanted device stimulates the neural target for up to 60 days at which point the leads are extracted. Patients have demonstrated prolonged analgesia continuing after extraction of the leads. The purpose of this case series is to demonstrate peripheral neural targets that could feasibly be used to treat various pain syndromes prevalent in the oncologic population. Materials and Methods A temporary, percutaneous PNS was implanted under ultrasound guidance in 12 oncologic chronic pain patients seen in an outpatient pain clinic who had failed medical and/or interventional management. The device was implanted for up to 60 days. Clinical progress of pain and functional capacity was monitored through regular clinical visits. Results The case series presents seven successful cases of implementation of the PNS to treat oncologic pain. Three of these cases demonstrate targeting of proximal spinal nerves to treat truncal neuropathic pain and lumbar radicular pain. The four remaining cases demonstrate successful targeting of other peripheral nerves and brachial plexus. We also share five failed cases without adequate pain relief with PNS. Conclusions PNS has potential uses in the treatment of oncologic pain. Further high‐quality studies should be designed to further elucidate use of the PNS to treat oncologic pain.

1 April 2015 in Pain Medicine
Verified
Journal Article
Open access
PDF file
AGAmitabh Gulati
Amitabh Gulati
RSRajiv Shah
Rajiv Shah
VPVinay Puttanniah
Vinay Puttanniah
JHJoseph C. Hung
Joseph C. Hung
VMVivek Malhotra
Vivek Malhotra
Tumors invading the chest wall and pleura are often incurable, and treatment is targeted toward palliation of symptoms and control of pain. When patients develop tolerance or side effects to systemic opioid therapy, interventional techniques can better optimize a patient's pain. We performed a retrospective review of 146 patients from April 2004 to January 2014 who underwent diagnostic and therapeutic procedures for pain relief. Using four patients as a paradigm for neurolytic approaches to pain relief, we present a therapeutic algorithm for treating patients with intractable thoracic chest wall pain in the oncologic population. For each patient, we describe the use of intercostal/paravertebral nerve blocks and neurolysis, pulsed radiofrequency ablation (PRFA) of the thoracic nerve roots, or intrathecal pump placement to successfully treat the patient's chest wall pain. Analysis of 146 patient charts is also performed to assess effectiveness of therapy. Seventy-nine percent of patients undergoing an intercostal nerve diagnostic blockade (with local anesthetic and steroid) stated that they had improved pain relief with 22% having prolonged pain relief (average of 21.5 days). Only 32% of successful diagnostic blockade patients elected to proceed to neurolysis, with a 62% success rate. Seven patients elected to proceed to intrathecal drug delivery. Intercostal nerve diagnostic blockade with local anesthetic and steroid may lead to prolonged pain relief in this population. Furthermore, depending on tumor location, we have developed a paradigm for the treatment of thoracic chest wall pain in the oncologic population.